NASDAQ: MNPR
Monopar Therapeutics Stock Ownership - Who owns Monopar Therapeutics?

Insider buying vs selling

Have Monopar Therapeutics insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Andrew CittadineChief Operating Officer2026-03-311,571$54.79
$86.08kSell
Chandler RobinsonChief Executive Officer2026-03-311,972$54.79
$108.05kSell
Andrew CittadineChief Operating Officer2025-12-311,889$65.30
$123.35kSell
Chandler RobinsonChief Executive Officer2025-12-312,558$65.30
$167.04kSell
Quan Anh VuChief Financial Officer2025-12-261,500$69.95
$104.93kBuy
Arthur J. KlausnerDirector2025-12-184,660$67.06
$312.50kSell
Arthur J. KlausnerDirector2025-12-18461$68.09
$31.39kSell
Chandler RobinsonChief Executive Officer2025-09-302,646$81.67
$216.10kSell
Andrew CittadineChief Operating Officer2025-09-301,896$81.67
$154.85kSell
Tactic Pharma LLCChief Executive Officer2025-09-24550,229$63.61
$35.00MSell

1 of 2

MNPR insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when MNPR insiders and whales buy or sell their stock.

MNPR Shareholders

What type of owners hold Monopar Therapeutics stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Arthur J. Klausner137.10%9,174,944$488.57MInsider
Michael J. 1. Brown71.81%4,805,470$255.89MInsider
Tactic Pharma LLC65.50%4,383,299$233.41MInsider
Janus Henderson Group PLC19.69%1,317,410$70.15MInstitution
Ra Capital Management LP9.97%667,207$35.53MInstitution
Adage Capital Partners GP LLC9.56%639,467$34.05MInstitution
Saturn V Capital Management LP4.87%325,701$17.34MInstitution
Vanguard Group Inc4.39%293,816$15.65MInstitution
Blackrock Inc3.81%254,857$13.57MInstitution
Adar1 Capital Management LLC3.50%233,908$12.46MInstitution

1 of 3

MNPR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
MNPR22.50%77.50%Net SellingNet Selling
CMPX79.90%20.10%Net BuyingNet Buying
IMRX49.10%21.85%Net BuyingNet Buying
IRD8.23%91.77%Net SellingNet Selling
ALT42.17%48.80%Net BuyingNet Buying

Monopar Therapeutics Stock Ownership FAQ

Who owns Monopar Therapeutics?

Monopar Therapeutics (NASDAQ: MNPR) is owned by 82.52% institutional shareholders, 284.24% Monopar Therapeutics insiders, and 0.00% retail investors. Arthur J. Klausner is the largest individual Monopar Therapeutics shareholder, owning 9.17M shares representing 137.10% of the company. Arthur J. Klausner's Monopar Therapeutics shares are currently valued at $488.57M.

If you're new to stock investing, here's how to buy Monopar Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.